Download our app Order a test
News

New breast cancer therapy a step closer to clinical trials

An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]

Read more
News

Activating p53 protein improves cancer-killing potential

Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more